Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-09-11-Speech-2-370-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-09-11"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"it"^^xsd:language2
lpv:document identification number	"en.20120911.32.2-370-500"2
lpv:hasSubsequent	lp_eu:2012-09-11-Speech-2-371-0002
lpv:speaker	lp:Elisabetta Gardini2
lpv:spokenAs	substitute; ITRE (2012-05-24--2014-06-30)3 member; Delegation to the EU-Russia Parliamentary Cooperation Committee (2009-09-16--2014-06-30)3 member; ENVI (2012-01-19--2014-06-30)3 substitute; Delegation for relations with the United States (2009-09-16--2014-06-30)3 member; EPP (2009-07-14--2014-06-30)3 unknown; Il Popolo della Libertà (2009-07-14--2013-12-16)3
lpv:translated text	"The legislative proposal stems from a desire to ensure that certain provisions are observed, as not doing so would result in serious risks to health. Recent cases have, indeed, demonstrated the urgent need to improve the system of surveillance of medicinal products in order to strengthen the system currently in place. The agreement that has been reached is, therefore, a clear signal of our intention to address the shortcomings of the previous system. The vote in this House demonstrates a desire to establish a European system to evaluate potential problems with medicinal products. The new legal framework will allow for better monitoring of businesses: at last, companies withdrawing a drug from the market will not be able to hide behind ‘business reasons’, but will be forced to provide accurate and precise explanations."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph